PE20212247A1 - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos - Google Patents
Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estosInfo
- Publication number
- PE20212247A1 PE20212247A1 PE2021000924A PE2021000924A PE20212247A1 PE 20212247 A1 PE20212247 A1 PE 20212247A1 PE 2021000924 A PE2021000924 A PE 2021000924A PE 2021000924 A PE2021000924 A PE 2021000924A PE 20212247 A1 PE20212247 A1 PE 20212247A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- alkyl
- amino
- unsubstituted
- aminophenyl
- Prior art date
Links
- HWWKOVGSUZFLBU-UHFFFAOYSA-N NC1=CC=CC(NC2C(NC(=O)CC2)=O)=C1 Chemical class NC1=CC=CC(NC2C(NC(=O)CC2)=O)=C1 HWWKOVGSUZFLBU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Chemical class 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 102000001307 androgen receptors Human genes 0.000 abstract 3
- 108010080146 androgen receptors Proteins 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La invencion se refiere a compuestos derivados de 3-((3-aminofenil)amino)piperidina-2,6-diona de formula (IA); en donde RN es H; cada R1 se selecciona de halogeno, CN y C1-3 alquilo; cada R2 y R3 se selecciona independientemente de H y C1-3 alquilo, o R2 y R3 y el carbono al que estan unidos forman un C3-6 cicloalquilo sustituido o no sustituido; cada R4 es C1-3 alquilo sustituido o no sustituido, o dos grupos R4, junto con el mismo atomo de carbono o atomo o atomos de carbono adyacentes a los que estan unidos, forman un C3-6 cicloalquilo sustituido o no sustituido, o dos grupos R4 junto con los atomos de carbono no adyacentes a los que estan unidos forman un heterociclilo de 4-7 miembros sustituido o no sustituido; X es N; L es -O(C1-6 alquilo)- o -(C1-9 alquilo)-; n es 0-4; m es 0-8. Un compuesto seleccionado es formiato de 2-(4-(2-(4-(3-(6-ciano-5-(trifluorometil)piridin-3-il)-5,5-dimetil-4- oxo-2-tioxoimidazolidin-1-il)fenoxi)etil)piperazin-1-il)-N-(3-((2,6-dioxopiperidin-3- il)amino)fenil)acetamida. Dichos compuestos son mediadores de los receptores androgenico (AR), siendo utiles para el tratamiento de enfermedades mediadas por AR, tal como el cancer de prostata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212247A1 true PE20212247A1 (es) | 2021-11-24 |
Family
ID=71098067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000924A PE20212247A1 (es) | 2018-12-19 | 2019-12-18 | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11149007B2 (es) |
| EP (1) | EP3897636A4 (es) |
| JP (1) | JP7494181B2 (es) |
| KR (1) | KR20210118816A (es) |
| CN (1) | CN113453681A (es) |
| AU (1) | AU2019403207A1 (es) |
| BR (1) | BR112021011968A2 (es) |
| CA (1) | CA3124130A1 (es) |
| CL (1) | CL2021001665A1 (es) |
| CO (1) | CO2021007973A2 (es) |
| IL (1) | IL284223A (es) |
| MX (1) | MX2021007473A (es) |
| PE (1) | PE20212247A1 (es) |
| SG (1) | SG11202106507RA (es) |
| TW (1) | TWI820276B (es) |
| WO (1) | WO2020132014A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202039434A (zh) | 2018-12-19 | 2020-11-01 | 美商西建公司 | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 |
| US11149007B2 (en) * | 2018-12-19 | 2021-10-19 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| CN115175901B (zh) | 2019-12-19 | 2024-03-22 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| CN115955979A (zh) | 2020-06-24 | 2023-04-11 | 新基公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| US11560371B2 (en) | 2020-06-24 | 2023-01-24 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| KR20230027066A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| JP2024500377A (ja) | 2020-12-14 | 2024-01-09 | バイオセリックス， インコーポレイテッド | Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 |
| EP4359407A1 (en) * | 2021-06-25 | 2024-05-01 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| WO2022272053A1 (en) * | 2021-06-25 | 2022-12-29 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| WO2024102706A1 (en) * | 2022-11-09 | 2024-05-16 | Bristol-Myers Squibb Company | Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| TW200621723A (en) | 2004-09-09 | 2006-07-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivative and use thereof |
| US7576106B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US20080064876A1 (en) | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| JP5833681B2 (ja) | 2011-03-10 | 2015-12-16 | 蘇州開拓薬業有限公司Ｓｕｚｈｏｕｋｉｎｔｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アンドロゲン受容体アンタゴニストおよびその使用 |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| US9586947B2 (en) | 2012-09-04 | 2017-03-07 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Imidazoline derivatives, preparation methods thereof, and their applications in medicine |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| ES2620379T3 (es) | 2013-01-31 | 2017-06-28 | Vertex Pharmaceuticals Inc. | Quinolina y quinoxalina amidas como moduladores de canales de sodio |
| KR20210132233A (ko) | 2014-04-14 | 2021-11-03 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016291578C1 (en) | 2015-07-10 | 2021-07-15 | Arvinas Operations, Inc. | MDM2-based modulators of proteolysis and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2018009694A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| SI3660004T1 (sl) | 2016-10-11 | 2023-08-31 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| RU2747260C2 (ru) | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| CN110612294B (zh) | 2017-01-31 | 2024-01-16 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| WO2019106691A1 (en) | 2017-11-28 | 2019-06-06 | Aarti Industries Limited | Process for preparation of enzalutamide using novel intermediate |
| CN111163638B (zh) | 2017-12-05 | 2023-07-25 | 美国陶氏益农公司 | 杀有害生物组合物和方法 |
| EP3805231A4 (en) | 2018-05-30 | 2022-01-12 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | INHIBITOR CONTAINING A TRICYCLIC DERIVATIVE, METHOD FOR PREPARING IT AND ITS APPLICATION |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| US11149007B2 (en) * | 2018-12-19 | 2021-10-19 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| TW202039434A (zh) | 2018-12-19 | 2020-11-01 | 美商西建公司 | 經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法 |
-
2019
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 JP JP2021535539A patent/JP7494181B2/ja active Active
- 2019-12-18 TW TW108146514A patent/TWI820276B/zh active
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/es unknown
- 2019-12-18 AU AU2019403207A patent/AU2019403207A1/en active Pending
- 2019-12-18 KR KR1020217019479A patent/KR20210118816A/ko unknown
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/es unknown
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/pt unknown
- 2019-12-18 CN CN201980092358.2A patent/CN113453681A/zh active Pending
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 EP EP19901383.0A patent/EP3897636A4/en active Pending
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en active Application Filing
-
2021
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/es unknown
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/es unknown
- 2021-06-20 IL IL284223A patent/IL284223A/en unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124130A1 (en) | 2020-06-25 |
| AU2019403207A1 (en) | 2021-07-15 |
| IL284223A (en) | 2021-08-31 |
| MX2021007473A (es) | 2021-08-05 |
| EP3897636A1 (en) | 2021-10-27 |
| SG11202106507RA (en) | 2021-07-29 |
| TWI820276B (zh) | 2023-11-01 |
| KR20210118816A (ko) | 2021-10-01 |
| US20200199073A1 (en) | 2020-06-25 |
| CN113453681A (zh) | 2021-09-28 |
| US20230002321A1 (en) | 2023-01-05 |
| EP3897636A4 (en) | 2022-09-07 |
| US11149007B2 (en) | 2021-10-19 |
| US11873283B2 (en) | 2024-01-16 |
| CL2021001665A1 (es) | 2022-01-14 |
| CO2021007973A2 (es) | 2021-09-09 |
| WO2020132014A1 (en) | 2020-06-25 |
| JP2022514344A (ja) | 2022-02-10 |
| BR112021011968A2 (pt) | 2021-09-08 |
| TW202039435A (zh) | 2020-11-01 |
| JP7494181B2 (ja) | 2024-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| PE20190409A1 (es) | Compuesto heterociclico | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR102426A1 (es) | Compuestos de indolcarboxamida como inhibidores de btk | |
| PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| PE20181449A1 (es) | Compuestos utiles como inhibidores de cinasa | |
| TR201909160T4 (tr) | Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri. | |
| PE20160995A1 (es) | Inhibidores de syk | |
| PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
| AR086198A1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
| PE20180233A1 (es) | Nuevos compuestos biciclicos como inhibidores duales de atx / ca | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR075635A1 (es) | N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos | |
| RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
| PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PE20080068A1 (es) | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt |